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Abstract
Background: Alternative therapeutic strategies are needed for localized oro-
pharyngeal carcinoma. Cetuximab represents a potential option for those ineligi-
ble for cisplatin or, until recently, an agent for de-escalation in low risk HPV+
oropharyngeal carcinoma (OPSCC). Our objective was to define the toxicity and
efficacy of cetuximab-radiotherapy.
Methods: We conducted paired phase II trials evaluating cetuximab-
radiotherapy in two cohorts (a) low risk HPV+ OPSCC and (b) cisplatin ineligi-
ble. The mean follow-up was 48 months.
Results: Forty-two patients were enrolled in cohort A with a 2-year disease
free survival (DFS) of 81%. Twenty-one patients were enrolled in cohort B prior
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to closure due to adverse outcomes with a 2-year DFS of 37%. Severe toxicities
were seen in 60% of patients, 30% required enteral nutrition.
Conclusion: Among cisplatin ineligible patients, cetuximab treatment engen-
dered poor outcomes. Rates of severe toxicities were on par with platinum-
based regimens suggesting that cetuximab is not a benign treatment.
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1 | INTRODUCTION
Head and neck squamous cell carcinoma is the sixth
most common malignancy with the majority of patients
presenting with advanced disease.1,2 The addition of
platinum-based chemotherapy to radiotherapy is a stan-
dard of care for locally advanced disease.3,4 However, the
addition of cisplatin is associated with significant toxic-
ities, prompting investigators to look for alternate thera-
peutic regimens.5
In an era of HPV related (HPV+) oropharyngeal
squamous cell carcinoma (OPSCC), long term toxicities
related to cisplatin and radiation are concerning in a
highly curable and often younger population.6 Cetuximab
is the only non-cisplatin radiosensitizing therapy for head
and neck cancer supported by randomized phase III trial
data.7 Initial evidence suggested that the addition of
cetuximab to radiation resulted in minimal increase in
toxicity with significant improvement in locoregional
control and survival. Furthermore, the degree of survival
improvement seen in the subset with oropharyngeal can-
cer seemed to mirror that observed in cisplatin trials.
Hence, the substitution of cetuximab for cisplatin became
a de-escalation strategy of interest to decrease the
treatment-associated toxicities while maintaining survival
outcomes.
Beyond the HPV+ OPSCC population, there is also sig-
nificant interest in finding alternatives to cisplatin in
patients with baseline organ dysfunction, poor perfor-
mance status, and medical comorbidities. Furthermore,
meta-analyses suggest a lack of benefit to the addition of
cisplatin patients ≥ 70 years old.4 Although cetuximab
may be a viable substitute, it is still associated with poten-
tially severe toxicities including acneiform rash and infu-
sion reactions which may impair the delivery of curative
doses of radiation. At the 5-year follow-up analysis, a sub-
set analysis suggested a lack of benefit in the addition of
cetuximab to radiation in patients ≥ 65 years old as well
as those with a KPS performance status of 60% to 80%.7-9
Although hypothesis generating, these observations were
based on small numbers of patients. To date, no clinical
trial has been performed specifically to evaluate the effi-
cacy and tolerability of cetuximab in this setting.
Recognizing the potential therapeutic roles for
cetuximab, we conducted paired, multicenter phase II tri-
als to characterize the efficacy and toxicity in two distinct
patient cohorts: (a) low risk HPV+ OPSCC; and
(b) ≥ 70 years old or not-eligible for cisplatin.
2 | MATERIALS AND METHODS
2.1 | Patient eligibility
These were paired multicenter phase 2 open-label trials reg-
istered with the National Cancer Institute (NCT01663259,
NCT00904345), independently reviewed, and approved by
the Institutional Review Boards (IRBMED) of both partici-
pating centers; the University of Michigan Rogel Cancer
Center (UMCC) and Ann Arbor Veterans Affairs Medical
Center (AAVAMC). All patients provided written informed
consent. This trial was conducted in full accordance with
World Medical Association Declaration of Helsinki and
local IRB ethical requirements.
Inclusion criteria for the low risk cohort (cohort A)
stipulated pathologically confirmed, previously untreated
stage III-IV squamous cell carcinoma of the oropharynx,
p16 expression on pre-treatment biopsy, smoking history
less than 10 pack-years, and ECOG ≤1. Patients' tumors
were staged following the AJCC seventh edition
criteria.10 Tumors were defined as p16 positive if ≥ 70%
of tumor cells demonstrated strong and diffuse nuclear
and cytoplasmic staining.11
Inclusion criteria for the non-cisplatin eligible cohort
(cohort B) consisted of pathologically-confirmed, previ-
ously untreated locally advanced squamous cell carcinoma
of the larynx, hypopharynx, oropharynx, oral cavity, or
unresectable head and neck cutaneous squamous cell car-
cinomas. Eligible patients were required to have met at
least one of the following criteria (a) age ≥ 70 years old,
(b) ECOG ≥1, (c) creatinine clearance <30 cc/min, and/or
(d) co-morbidities that precluded treatment with standard
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platinum-based chemotherapy as determined by the
treating physician. Patients with nasopharyngeal squa-
mous cell carcinoma were excluded.
In both cohorts, patients were required to have ade-
quate hematopoietic and hepatic function defined as
WBC ≥ 3.5 × 109 cell/mL, absolute neutrophil count
≥1.5 × 109 cell/mL, platelets ≥100 000 cells/mm3, con-
centration of total serum bilirubin less than 1.5 times the
upper limit of normal (ULN) as well as aspartate amino-
transferase (AST) and alanine aminotransferase (ALT)
within 2.5 × institutional upper limits of normal. Patients
with a history of head and neck radiation or chemother-
apy, prior head and neck malignancy, previous treatment
with anti-EGFR directed therapy, or documented distant
metastases were excluded.
2.2 | Staging and treatment
Pretreatment assessment of enrolled patients included a
complete history and physical examination by all multi-
disciplinary teams (Otolaryngology, Radiation Oncology,
and Medical Oncology), baseline laboratory studies (CBC
with differential, comprehensive metabolic profile), and
radiographic staging studies (PET-CT, CT, or MRI of the
head and neck as clinically warranted). All screening
assessments were completed within 28 days prior to the
start of treatment.
Radiotherapy started 5 to 7 days after loading dose
of cetuximab and consisted of daily fractionated IMRT
delivered over 35 fractions. In cohort A, the total dose
delivered to the planning target volume (PTV) high
was 70Gy and PTVlow was 56Gy where gross tumor
volume (GTV) was expanded by 3 to 5 mm to create
clinical target volume (CTV) 70. In cohort B, a PTVmid
to 63Gy was used for high risk nodal volumes at the
discretion of treating physicians. PTV expansion was
3 mm from CTV in all patients. Interruption in treat-
ment was defined as greater than four scheduled radia-
tion treatments missed (≥ 54 days from initiation to
completion of radiotherapy).
Cetuximab was delivered as a loading dose of
400 mg/m2 administered 1 week prior to the start of
radiotherapy. Premedication with acetaminophen,
diphenhydramine, famotidine, and hydrocortisone was
administered prior to every dose of cetuximab. Criteria
for drug interruption and dose reduction were specified
per protocol. Cetuximab 250 mg/m2 was administered
weekly during radiation. Patients were seen weekly by
both Radiation Oncology and Medical Oncology during
which toxicities were graded. Treatment-related adverse
events were graded according to the Common Terminol-
ogy for Adverse Events version 4.0 (CTCAE v4). At
12-14 weeks post completion of radiation restaging imag-
ing (PET-CT or MRI at the discretion of the treating phy-
sician) was performed to evaluate clinical response to
therapy. Patients were seen for study related follow-up at
1 month, 12 to 14 weeks, 1 and 2 years post completion
of radiation at which point toxicities were recorded.
2.3 | Statistical analysis
Proposed sample sizes for each cohort (n = 43 cohort A;
n = 50 cohort B) were predetermined based on simula-
tions using cohort specific preliminary data and objec-
tives assuming 85% of accrued patients would be
evaluable for the primary endpoint, progression free sur-
vival. A previously published institutional clinical trial
was utilized as a historical control. In this cohort,
patients with oropharyngeal cancer were treated with
daily fractionated IMRT and weekly carboplatin and pac-
litaxel for radiosensitization with survival on par with cis-
platin regimens.12 The primary objective of efficacy for
cohort A was powered to provide sufficient evidence to
justify a future multi-institutional study and not formally
test non-inferiority. Proceeding with a phase III multi-
institutional study required that cohort A demonstrates
evidence of similar survival outcomes and lower rates of
toxicities (including weight loss and enteral feeding tube
use) compared to a historical control treated with
platinum-based therapy. Power for a test of biomarker
association with progression-free survival was considered
for cohort B. All enrolled patients were evaluable for tox-
icity. Patients were evaluable for response if they com-
pleted the entire course of cetuximab and radiation or if
radiation and/or cetuximab was stopped or modified due
to toxicity.
Treatment-related adverse events (CTCAE v4) were
graded for each trial and assigned an attribution. The
highest grade observed for recurring toxicities was
recorded. Adverse events definitely, probably, or possibly
related to treatment were tabulated for comparison.
Acute toxicities were defined as those occurring within
180 days of treatment completion. Freedom from local
regional progression (FFLRP) was defined as time from
enrollment to first local or regional failure. Disease free
survival (DFS) was defined as time from enrollment to
the first event of either recurrent disease or death. Over-
all survival (OS) was defined as time from enrollment to
death from any cause, or date of last follow-up for alive
patients. Survival estimates were calculated using
Kaplan-Meier methods, and the confidence intervals
were calculated by the Greenwood method. All analyses
were performed using SAS v9.4 software and R ver-
sion 3.5.2.
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3 | RESULTS
3.1 | Patient characteristics
From February 2009 to May 2016, a total of 63 patients
were enrolled and treated with concurrent radiation and
cetuximab. (Figure 1). The patient characteristics are sum-
marized in Table 1. Overall, the median age was 61 years
old (range: 39-85) and the majority of participants were
male (n = 53, 84%). Cohort A completed accrual while
cohort B stopped early due to concerns regarding toxicity
and frequency of disease persistence.
Cohort A consisted of 42 patients, all of whom had
HPV positive squamous cell carcinoma of the oropharynx.
The majority were nonsmokers, however, 14% of patients
had a greater than 10 pack-year smoking history. Five per-
cent of patients had T4 and 7% had ≥ N2c disease by AJCC
seventh edition. Post hoc staging by AJCC eighth edition13
demonstrated 81% (n = 34) patients to have stage I disease,
14% (n = 6) with stage II, and 5% (n = 2) with stage III.
Cohort B consisted of 21 patients of which nearly all
patients were either current active smokers (n = 7, 33%) or
former smokers with greater than 10 pack-year history
(n = 13, 62%). The pretreatment Charlson comorbidity index
(CCI) was calculated and most patients were found to have
low level comorbidities (n = 12, 57%); however, a significant
number of patients had advanced level comorbidities (n = 7,
33%). The most common primary site was the oropharynx
(n = 16, 76%). Characterization of the extent of disease by
TNM staging demonstrated that most patients had stage
IVA disease (stage III: n = 6, 28%, stage IVA: n = 10, 48%,
stage IVB: n = 5, 34%). HPV status was known in most
patients (16/21) of which 10 were HPV positive (48%).
3.2 | Treatment compliance
Cetuximab based radiotherapy was administered per pro-
tocol in all 42 patients of the low risk HPV+ cohort
(Table 2). A total of 23 patients (55%) who received at
least seven doses of cetuximab and planned 70 Gy dose of
radiation was delivered in all 42 patients. One patient
(2%) had an interruption in radiation. A mean weight
loss of 8% starting body weight was observed and
11 patients (26%) required enteral tube placement during
therapy.
Among cohort B, radiotherapy plus cetuximab was
administered per protocol in 18 patients. Three patients
did not complete study treatment with concurrent radia-
tion and cetuximab. One patient discontinued
cetuximab after a hypersensitivity reaction during the
loading dose and was treated with radiotherapy alone.
Three patients (14%) had radiation interruptions rang-
ing from one to 26 days. Radiation and cetuximab were
both discontinued in two additional patients (9%) due to
radiation associated toxicities—one after 42 Gy and the
other after 32 Gy. Eighteen patients (86%) had no inter-
ruption in their radiation therapy. Fourteen patients
(63%) had at least seven doses of cetuximab. The mean
weight loss was 11% (maximum of 14%) and eight
FIGURE 1 This figures illustrates the enrollment and follow-up status for all patients involved with the paired clinical trials
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TABLE 1 Patient and tumor characteristics
Total population
Cohort A Cohort B
Characteristic (Low risk HPV+) (Non-platinum eligible)
Patients, number 63 42 21
Age, years (range) 60.8(39-85) 58.4 (43-76) 65.6 (39-85)
Sex, no. patients (%)
Male 53 (84%) 36 (86%) 17 (81%)
Female 10 (16%) 6 (14%) 4 (19%)
ECOG performance status, no. patients (%)
0 40 (63%) 37 (88%) 3 (14%)
1 18 (29%) 4 (9%) 14 (67%)
2 3 (5%) 0 (0%) 3 (14%)
3 1 (2%) 0 (0%) 1 (5%)
Charlson comorbidity Index, no. patients (%)
0 36 (57%) 34 (81%) 2 (9%)
1 19 (30%) 7 (17%) 12 (57%)
2 5 (8%) 1 (2%) 4 (19%)
3 2 (3%) 0 (0%) 2 (9%)
4 1 (2%) 0 (0%) 1 (5%)
Smoking, no. patients (%)
Yes, current 8 (13%) 1 (2%) 7 (33%)
Yes, past 18 (29%) 5 (12%) 13 (62%)
No 37 (59%) 36 (86%) 1 (5%)
Cancer location, no. patients (%)
Oropharynx 58 (92%) 42 (100%) 16 (76%)
Oral cavity 2 (3%) 0 (0%) 2 (9%)
Auditory canal 1 (2%) 0 (0%) 1 (5%)
Hypopharynx 1 (2%) 0 (0%) 1 (5%)
Unknown primary 1 (2%) 0 (0%) 1 (5%)
TNM Stage (AJCC 7), no. patients (%)
II 1 (2%) 1 (2%) 0 (0%)
III 11 (17%) 5 (12%) 6 (28%)
IVA 46 (73%) 36 (86%) 10 (48%)
IVB 5 (8%) 0 (0%) 5 (24%)
T Classification, no. patients (%)
T0 1 (2%) 0 (0%) 1 (5%)
T1-T2 44 (70%) 36 (86%) 8 (38%)
T3 10 (16%) 4 (9%) 6 (29%)
T4a-T4b 8 (13%) 2 (5%) 6 (29%)
N Classification, no. patients (%)
N0-N1 15 (24%) 7 (17%) 8 (38%)
N2a-N2b 39 (62%) 32 (76%) 9 (43%)
N2c-N3 7 (11%) 3 (7%) 4 (19%)
HPV Status, no. patients (%)
Positive 52 (82%) 42 (100%) 10 (48%)
Negative 6 (9%) 0 (0%) 6 (29%)
Unknown 5 (8%) 0 (0%) 5 (24%)
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patients (38%) required G-tube placement during
treatment.
3.3 | Treatment toxicity
Among all 63 patients included in the study, ≥ grade
three toxicities were seen in 60% of patients (Table 2).
Select grade three toxicities of interest included mucositis
in 43%, cutaneous toxicity in 11%, 19% dysphagia, and 9%
hematologic toxicity (Table 3). Patients in cohort A had a
relatively higher rate of ≥ grade 3 toxicities (67%) relative
to those in cohort B (48%). Distribution of toxicities was
relatively similar between the two cohorts with more
grade 3 hematologic toxicity seen in cohort A (six
patients, 14%) whereas there was more grade 3 cutaneous
toxicity (four patients, 19%) in cohort B. No grade 5 toxic-
ities were seen in either cohort.
TABLE 2 Treatment characteristics and compliance
Total population
Cohort A Cohort B
Characteristic (Low risk HPV+) (Non-platinum eligible)
RT interruption, no. patients (%)
None 59 (94%) 41 (98%) 18 (86%)
Yes 4 (6%) 1 (2%) 3 (14%)
Treatment discontinuation, no. patients (%)
Radiation discontinuation 2 (3%) 0 (0%) 2 (9%)
No. of cetuximab doses
8+ 15 (24%) 3 (7%) 12 (57%)
7 22 (35%) 20 (48%) 2 (9%)
5-6 21 (33%) 17 (40%) 4 (19%)
3-4 3 (5%) 1 (2%) 2 (9%)
1-2 0 (0%) 0 (0%) 0 (0%)
0 1 (2%) 0 (0%) 1 (5%)
Cetuximab dosage reduction, no. patients (%)
No 61 (97%) 42 (100%) 19 (90%)
Yes, 80% 1 (2%) 0 (0%) 1 (5%)
AEs possibly related to treatment, no. patients (%)
None 1 (2%) 0 (0%) 1 (5%)
Mild–moderate (grade 1 or 2) 24 (38%) 14 (33%) 10 (48%)
Severe (grade 3 or 4) 38 (60%) 28 (67%) 10 (48%)
Enteral Nutrition During Treatment, no. patients (%) 19 (30%) 11 (26%) 8 (38%)
Weight loss, % mean (SD) max mean (SD) max mean (SD) max
initial to end of treatment 7% (0.04) 15% 8% (0.04) 15% 5% (0.05) 14%
initial to minimum weight 13% (0.06) 28% 14%(0.06) 28% 11% (0.05) 21%
TABLE 3 Treatment related toxicities
Cohort A Cohort B
Total population (Low risk HPV+) (Non-platinum eligible)
All grades Grades 3-4 All grades Grades 3-4 All grades Grades 3-4
Cutaneous toxicity 54 (86%) 7 (11%) 38 (90%) 3 (7%) 16 (76%) 4 (19%)
Mucositis 61 (97%) 27 (43%) 42 (100%) 19 (45%) 19 (90%) 8 (38%)
Dysphagia 51 (81%) 12 (19%) 37 (88%) 7 (17%) 14 (67%) 5 (24%)
Hematologic Toxicity 16 (25%) 6 (9%) 13 (31%) 6 (14%) 3 (14%) 0 (0%)
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3.4 | Outcomes
The median follow-up was 48 months. Kaplan-Meier sur-
vival analysis for overall survival (Figure 2A), disease free
survival (Figure 2B), disease-specific survival (Figure 2C),
and freedom from locoregional progression (Figure 2D)
were performed independently for each cohort. In the
cohort A, the 1 and 2-year disease free survival were 86%
(95% CI: 76%-97%) and 81% (95% CI: 70%-94%), respec-
tively with corresponding 1 and 2-year overall survival of
98% (95% CI: 93%-100%) and 95% (95% CI: 89%-100%)
(Table 4). One patient had a local failure, four patients
had regional failure, and two patients had distant
metastases.
TABLE 4 Treatment Efficacy and Survival
Cohort A Cohort B
(Low risk HPV+) (Non-platinum eligible)
Patients 42 21
Disease Free Survival
1 year 85.7% (75.8-97.0%) 47.8% (29.9-76.5%)
2 year 81.0% (69.9-93.7%) 37.2% (20.7-66.8%)
Overall Survival
1 year 97.6% (93.1-100.0%) 68.8% (50.9-93.0%)
2 year 95.2% (89.0-100.0%) 47.6% (29.7-76.3%)
FFLRPa
1 year 87.9% (78.4-98.4%) 63.9% (44.5-92.0%)
2 year 87.9% (78.4-98.4%) 51.2% (31.7-82.5%)
aFFLRP—Freedom from local regional progression.
FIGURE 2 These figures demonstrate overall survival, A, disease free survival, B, disease specific survival, C, and freedom from
locoregional progression, D, for each cohort
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At the time of analysis, in the non-cisplatin eligible
cohort, eight patients are alive with a median follow up
of 48 months. One patient was lost to follow up shortly
after the completion of treatment. Fifteen patients had
planned reimaging 3 months after the completion of radi-
ation. Two patients died prior to posttreatment restaging
imaging and response assessment was missing for an
additional four patients. Eleven patients (73%) had tumor
clearance (radiographic complete response) on their post-
treatment imaging whereas four patients (27%) had per-
sistent disease. The estimated overall survival was 68.8%
(95% CI: 50.9%-93.0%) at 1 year and 47.6% (95% CI:
29.7%-76.3%) at 2 years. The estimated disease free sur-
vival was 47.8% (95% CI: 29.9%-76.5%) at 1 year and
37.2% (95% CI: 20.7%-66.8%) at 2 years. The disease-
specific survival at 2 years was 52.9% (95% CI:33.8%-
82.9%). Eleven patients developed recurrent disease. Pat-
terns of recurrence varied significantly; six patients had
both local and regional recurrence, one patient had local
and distant recurrence, one patient had a regional failure,
and three patients had distant metastases alone.
4 | DISCUSSION
These paired multicenter phase II trials characterize the
outcomes of cetuximab based radiotherapy in both low
risk HPV+ OPSCC patients and those ineligible for cis-
platin. The findings of this study are timely given the
publication of RTOG 1016 and the unanswered question
of alternative agents for radiosensitization in specific
cohorts of locally advanced HNSCC.
HPV+ OPSCC has been demonstrated to have better
response to treatment compared to stage matched HPV-
OPSCC. Low risk HPV+ OPSCC risk disease (defined as
AJCC seventh Edition non-T4 and less than N2b with
a < 10 pack-year history) has been shown to have a high
overall survival of 93% at 3 years with cisplatin based
radiation.14,15 Among the cohort with low risk HPV+
OPSCC our study, the impressive overall survival was on
par with previous findings.12,16 Of note, due to evolving
definitions of low risk,15 two patients were included
whom would now be considered high risk HPV+ OPSCC
and hence not eligible for de-escalation trials. The recent
publication of two-phase III trials (De-ESCALaTE and
RTOG 1016) have highlighted the inferiority of
cetuximab vs cisplatin. De-ESCALaTE was powered to
assess rates of severe toxicity with cetuximab vs cisplatin
and indeed demonstrated equivalent rates of toxicities
between the agents. However, treatment with cetuximab
was found to be associated with a potentially impaired
overall survival vs cisplatin (2-year overall survival 89.4%
vs 97.5%).17 The non-inferiority trial RTOG 1016
definitively demonstrated the 5-year overall survival was
significantly worse with radiotherapy plus cetuximab vs
cisplatin (77.9% vs 84.9%).18 In comparison, we demon-
strated a higher overall survival at one and 2-year sur-
vival in patients treated with cetuximab roughly
equivalent to the HPV+ subgroup analysis of IMC-9815.9
Of note, RTOG 1016 included a significant population of
patients which would not be considered low risk HPV+
OPSCC given their advanced stage disease (T4 or greater
than N2b by AJCC seventh Edition) or smoking history
(>10 pack years) which could potentially have affected
these comparisons. Similarly, the overall survival in our
trial was superior to published outcomes of cetuximab
based radiotherapy in oropharyngeal cancer, albeit our
study focused solely on patients with disease considered
low risk.8
Although a high overall survival rate was seen in
cohort A, the disease free survival seen in this low risk
cohort was lower than that seen with historical cohorts
treated with platinum-based chemoradiation, but similar
to previous reports of cetuximab based radiotherapy in
HPV+ OPSCC.8,12,16 This extends and supports the find-
ing of decreased progression free survival in patients
treated with cetuximab radiotherapy vs cisplatin in both
RTOG 1016 and De-ESCALaTE.17,18
Patients who are ineligible for cisplatin do not have
evidence supporting the safety and efficacy of radio-
sensitizing therapeutics. Although age has previously
been considered a contraindication to cisplatin, reviews
of the National Cancer Database have shown an
improvement in survival with the addition of chemother-
apy to radiotherapy regardless of age.19-21 This empha-
sizes the need for investigation of radiosensitizing
therapeutics in older patients and those with contraindi-
cations to cisplatin. Cetuximab has been proposed given
the lack of contraindications with solid organ impair-
ment and differential mechanism of action compared to
traditional cytotoxic agents. In fact, the IMC-9815 trial
demonstrated no increased toxicities with the addition of
cetuximab compared to radiotherapy alone.7 Although
data in cohort B was limited due to early closure, both
the overall and disease free survival rates were lower
compared to those reported in either arm of IMC-9815.
Our study exclusively targeted patients with a poor per-
formance status and/or older than 65, a population which
previously was suggested to have not garnered benefit
with the addition of cetuximab.22 Beyond impaired per-
formance status and age, patients in cohort B were at
high risk of recurrence as they were primarily stage IVA,
current or past smokers, and had a large population of
HPV-patients.
Toxicities are important to consider especially when
dealing with both low risk or frail populations. De-
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escalation of therapy with alternate chemotherapeutics in
low risk HPV+ OPSCC has been an intense area of inter-
est. To be suitable for de-escalation, a regimen must
decrease toxicity while maintaining excellent outcomes.
Cetuximab has been considered as a potential agent for
de-escalation in low risk HPV+ OPSCC given its previ-
ously reported efficacy and lack of increase in toxicity over
radiotherapy alone. Our study supports that cetuximab is
associated with significant rates of serious adverse events,
albeit with a different profile.23 RTOG 1016 demonstrated
no difference in the rate of grade 3 to 4 toxicities between
patients treated with cisplatin and those treated with
cetuximab.18 Severe mucositis was seen in 43% of patients
overall (45% of the low risk cohort) which is seemingly
lower than the rates of 53-56% reported with platinum-
based regimens.12,18,23 Cutaneous toxicity is a known issue
with cetuximab based radiotherapy reported in 23-43% of
patients.7,18,23 We observed a much lower incidence of
severe cutaneous toxicity, possibly due to the institutional
use of prophylactic doxycycline and topical corticosteroids
prior to initiation of therapy.
Outside of these commonly reported toxicities, weight
loss and enteral nutrition can be significant contributors
to impairment in quality of life. Reducing weight loss and
the need for enteral nutrition are major aims when con-
sidering any treatment, especially those being used as an
approach of de-escalation or in a frail population. In our
study, patients lost an average of 7% of their starting body
weight and many patients enteral nutrition. This rate of
enteral nutrition is near identical to our previously
reported rate in patients with OPSCC treated with car-
boplatin and paclitaxel based radiotherapy (30% in this
study vs 29% previously).12 RTOG 1016 similarly reported
no difference in the rate of enteral nutrition between
patients treated with cisplatin vs cetuximab (57.3% vs
61.5%), although with higher overall feeding tube use.
Feeding tube rates in our study may be lower due to
smaller radiation target expansions and careful radiother-
apy sparing of normal tissues known to be associated
with dysphagia including pharyngeal constrictors.
Ongoing biomarker studies are underway to identify
patient populations who may have a greater response to
cetuximab. Tumor EGFR expression has not correlated
with response, but p16+ patients with KRAS variant have
been suggested to have greater benefit from cetuximab
when added to RT/cisplatin, and loss of PTEN expression
has been associated with decreased cetuximab
response.24,25 An immune mechanism for cetuximab
response has also been suggested.26 Immune markers
and downstream markers of EGFR from tumor and nor-
mal tissue collected on our trial pre and post cetuximab
administration are being investigated for correlation with
tumor response and toxicity.
Although these paired clinical trials provide insight
into the utility of cetuximab in important patient sub-
groups, our conclusions are limited given the relative
sample size and single arm design. Although a signifi-
cant limitation, the weakness of a lack of control arm
was compensated by use of a relatively matched histor-
ical control. This control consisted of a prospective
clinical trial performed at our institution in which
patients with OPSCC were treated with radiotherapy
plus carboplatin and paclitaxel and achieved excellent
survival and functional outcomes. Although survival in
cohort A was on par with our historical control, the
rate of severe toxicity was only modestly lower that
platinum based therapy. Therefore, the evidence was
insufficient to support a larger de-escalation trial uti-
lizing cetuximab.
The challenges are similar in the cohort of non-
cisplatin candidates which closed early due to high rate
of failure and toxicity. The premature closure of the trial
points to the potential for both poor outcomes and signif-
icant toxicities in this group at need of better treatment
options. In the cohort of patients who were not eligible
for cisplatin, cetuximab, and radiotherapy was associated
with poor patient outcomes including a high rate of toxic-
ity and recurrent disease. The findings of NRG HN004
will be important in assessing the future utility of
cetuximab and durvalumab in this non-cisplatin popula-
tion. A future challenge may be the lack of a control arm
of radiotherapy alone and/or an arm containing an alter-
native less toxic platinum regimen (ie, weekly carboplatin
and paclitaxel). Nevertheless, these findings will be piv-
otal in understanding how to best tailor therapy in
LAHNSCC.
In conclusion, cisplatin remains the standard of care
for concurrent chemoradiotherapy in the head and neck
among eligible patients.27 For those who are ineligible,
further studies are necessary to identify optimal treat-
ment alternatives.
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